CFN Media

April 12, 2017 09:00 ET

Cannabix Looks to Solve Roadside THC Testing Issues -- CFN Media

SEATTLE, WA--(Marketwired - Apr 12, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an article discussing Cannabix Technologies Inc.'s (CSE: BLO) (OTC PINK: BLOZF) recent progress in developing a roadside THC breathalyzer.

There's no question that marijuana impairment is causing issues on the nation's roadways. The NHTSA estimates that up to one-in-ten weekend nighttime drivers in the U.S. may have THC in their bodies, while the IIHS projects that THC's effects double a driver's crash risk. Colorado police found that marijuana-involved road fatalities have doubled in the state following recreational legalization -- a trend that could spread throughout the country.

Despite acknowledging the problem, there is widespread disagreement on the part of both regulators and medical professionals about how to test for marijuana impairment. Existing detection methods for cannabis use, including those based on blood, urine, and oral fluid (saliva) can detect THC and its metabolites many days or even weeks after the last cannabis intake, making it difficult, if not impossible, to determine recent cannabis intake accurately.

The ideal device for roadside testing would be a breathalyzer since it provides immediate feedback and is already in use by law enforcement and is understood by the public as a non-invasive tool. Unfortunately, police are limited to invasive blood tests or ineffective mouth swabs at the moment as breathalyzer technology is perfected. The good news is companies like Cannabix Technologies are drawing closer to developing a functional device that's ready for live use.

"The high resolving power of the FAIMS device with its capability for real time detection of THC and its metabolic breakdown products will aid in establishing key metrics for measuring in-vivo THC metabolism and should permit detection capabilities similar to that of blood tests. The current human testing on the FAIMS based Cannabix Marijuana Breathalyzer has shown impressive results thus far," said Cannabix Technologies' Dr. Raj Attariwala.

The company recently announced that preliminary testing on human subjects showed that its Beta prototype breathalyzer is capable of detecting THC in real-time in subjects that smoked THC cigarettes. In addition to detecting THC, the device detected 11-hydroxy-delta-9-tetrahydrocannabinol, delta-9-carboxy-tetrahydrocannabinol, and three other cannabinoids related to cannabigerol that could be valuable to law enforcement.

The company plans to further test its Beta and Beta 2.0 prototypes over the coming weeks, where it will calibrate decay signal intensities with a refined breath collection component. The goal is to enable the breakthrough device to zero in on impairment with 'recency of use' like no other device on the market. With a first-mover advantage, the company could rapidly build market share in both the United States and Canada and globally.

Please follow the link to read the full article:

Learn how to become a CFN Media featured company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the U.S. and Canada rely on CFN Media to grow and succeed.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information